Literature DB >> 22541966

Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis.

Susan L Tucker1, Minghuan Li, Ting Xu, Daniel Gomez, Xianglin Yuan, Jinming Yu, Zhensheng Liu, Ming Yin, Xiaoxiang Guan, Li-E Wang, Qingyi Wei, Radhe Mohan, Yevgeniy Vinogradskiy, Mary Martel, Zhongxing Liao.   

Abstract

PURPOSE: To determine whether single-nucleotide polymorphisms (SNPs) in genes associated with DNA repair, cell cycle, transforming growth factor-β, tumor necrosis factor and receptor, folic acid metabolism, and angiogenesis can significantly improve the fit of the Lyman-Kutcher-Burman (LKB) normal-tissue complication probability (NTCP) model of radiation pneumonitis (RP) risk among patients with non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Sixteen SNPs from 10 different genes (XRCC1, XRCC3, APEX1, MDM2, TGFβ, TNFα, TNFR, MTHFR, MTRR, and VEGF) were genotyped in 141 NSCLC patients treated with definitive radiation therapy, with or without chemotherapy. The LKB model was used to estimate the risk of severe (grade≥3) RP as a function of mean lung dose (MLD), with SNPs and patient smoking status incorporated into the model as dose-modifying factors. Multivariate analyses were performed by adding significant factors to the MLD model in a forward stepwise procedure, with significance assessed using the likelihood-ratio test. Bootstrap analyses were used to assess the reproducibility of results under variations in the data.
RESULTS: Five SNPs were selected for inclusion in the multivariate NTCP model based on MLD alone. SNPs associated with an increased risk of severe RP were in genes for TGFβ, VEGF, TNFα, XRCC1 and APEX1. With smoking status included in the multivariate model, the SNPs significantly associated with increased risk of RP were in genes for TGFβ, VEGF, and XRCC3. Bootstrap analyses selected a median of 4 SNPs per model fit, with the 6 genes listed above selected most often.
CONCLUSIONS: This study provides evidence that SNPs can significantly improve the predictive ability of the Lyman MLD model. With a small number of SNPs, it was possible to distinguish cohorts with >50% risk vs <10% risk of RP when they were exposed to high MLDs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22541966      PMCID: PMC3521878          DOI: 10.1016/j.ijrobp.2012.02.021

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Establishment of a Radiogenomics Consortium.

Authors:  Catharine West; Barry S Rosenstein; Jan Alsner; David Azria; Gillian Barnett; Adrian Begg; Søren Bentzen; Neil Burnet; Jenny Chang-Claude; Eric Chuang; Charlotte Coles; Kim De Ruyck; Dirk De Ruysscher; Alison Dunning; Rebecca Elliott; Laura Fachal; Janet Hall; Karin Haustermans; Carsten Herskind; Tobias Hoelscher; Takashi Imai; Mayumi Iwakawa; Don Jones; Cecilia Kulich; Jan-Hans Langendijk; Peter O'Neils; Mahmut Ozsahin; Matthew Parliament; Andrzej Polanski; Barry Rosenstein; Daniela Seminara; Paul Symonds; Chris Talbot; Hubert Thierens; Ana Vega; Catherine West; John Yarnold
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04       Impact factor: 7.038

Review 2.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.

Authors:  Susan L Tucker; Lei Dong; Walter R Bosch; Jeff Michalski; Kathryn Winter; Radhe Mohan; James A Purdy; Deborah Kuban; Andrew K Lee; M Rex Cheung; Howard D Thames; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-02       Impact factor: 7.038

4.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method.

Authors:  G J Kutcher; C Burman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

5.  Complication probability as assessed from dose-volume histograms.

Authors:  J T Lyman
Journal:  Radiat Res Suppl       Date:  1985

6.  Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy.

Authors:  N G Burnet; J Johansen; I Turesson; J Nyman; J H Peacock
Journal:  Int J Cancer       Date:  1998-12-18       Impact factor: 7.396

7.  Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.

Authors:  Xianglin Yuan; Zhongxing Liao; Zhensheng Liu; Li-E Wang; Susan L Tucker; Li Mao; Xin Shelley Wang; Mary Martel; Ritsuko Komaki; James D Cox; Luka Milas; Qingyi Wei
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

8.  Analysis of radiation pneumonitis risk using a generalized Lyman model.

Authors:  Susan L Tucker; H Helen Liu; Zhongxing Liao; Xiong Wei; Shulian Wang; Hekun Jin; Ritsuko Komaki; Mary K Martel; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

9.  Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy.

Authors:  Hekun Jin; Susan L Tucker; Hui Helen Liu; Xiong Wei; Sue Sun Yom; Shulian Wang; Ritsuko Komaki; Yuhchyau Chen; Mary K Martel; Radhe Mohan; James D Cox; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2008-10-18       Impact factor: 6.280

10.  Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.

Authors:  Xiaoxiang Guan; Ming Yin; Qingyi Wei; Hui Zhao; Zhensheng Liu; Li-E Wang; Xianglin Yuan; Michael S O'Reilly; Ritsuko Komaki; Zhongxing Liao
Journal:  BMC Cancer       Date:  2010-08-16       Impact factor: 4.430

View more
  28 in total

Review 1.  Effect of transforming growth factor-β1 869C/T polymorphism and radiation pneumonitis.

Authors:  Yingtian Wang; Xingguang Wang; Xiyan Wang; Deyong Zhang; Shujuan Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Treatment planning evaluation and optimization should be biologically and not dose/volume based.

Authors:  Joseph O Deasy; Charles S Mayo; Colin G Orton
Journal:  Med Phys       Date:  2015-06       Impact factor: 4.071

Review 3.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors:  Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal:  Cancer Discov       Date:  2014-01-17       Impact factor: 39.397

Review 4.  Radiogenomics and radiotherapy response modeling.

Authors:  Issam El Naqa; Sarah L Kerns; James Coates; Yi Luo; Corey Speers; Catharine M L West; Barry S Rosenstein; Randall K Ten Haken
Journal:  Phys Med Biol       Date:  2017-08-01       Impact factor: 3.609

Review 5.  Nondosimetric risk factors for radiation-induced lung toxicity.

Authors:  Feng-Ming Spring Kong; Shulian Wang
Journal:  Semin Radiat Oncol       Date:  2014-12-15       Impact factor: 5.934

Review 6.  Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy.

Authors:  Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2017-12

Review 7.  Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity.

Authors:  Barry S Rosenstein
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

Review 8.  The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention.

Authors:  Sarah L Kerns; Suman Kundu; Jung Hun Oh; Sandeep K Singhal; Michelle Janelsins; Lois B Travis; Joseph O Deasy; A Cecile J E Janssens; Harry Ostrer; Matthew Parliament; Nawaid Usmani; Barry S Rosenstein
Journal:  Semin Radiat Oncol       Date:  2015-05-15       Impact factor: 5.934

9.  Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma.

Authors:  Issam El Naqa; Adam Johansson; Dawn Owen; Kyle Cuneo; Yue Cao; Martha Matuszak; Latifa Bazzi; Theodore S Lawrence; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-01       Impact factor: 7.038

Review 10.  Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement.

Authors:  Dirk De Ruysscher; Gilles Defraene; Bram L T Ramaekers; Philippe Lambin; Erik Briers; Hilary Stobart; Tim Ward; Søren M Bentzen; Tjeerd Van Staa; David Azria; Barry Rosenstein; Sarah Kerns; Catharine West
Journal:  Radiother Oncol       Date:  2016-12-12       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.